Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05349890 | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | PHASE1 | ACTIVE NOT_RECRUITING | 1 | — | — | Apr 3, 2023 | Apr 15, 2028 | Apr 24, 2026 | 1 | United States |
Severity of adverse events using CTCAE version 5.0
| Arm | Type | Description |
|---|---|---|
| CDX-1140 + TCR-T + Pembro | EXPERIMENTAL | Patients will receive CDX-1440, TCR-T, and pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| TCR-transduced T cells | BIOLOGICAL | TSA-reactive TCR-engineered T cells |
| CDX-1140 | DRUG | Recombinant fully human IgG2κ monoclonal antibody |
| Pembrolizumab | DRUG | Humanized immunoglobulin G4 (IgG4) monoclonal antibody |
Inclusion Criteria: 1. Patients 18 years and older with metastatic or locoregionally advanced epithelial cancers, that are considered incurable. 2. Confirmation by Tran Laboratory of neoantigen-reactive TCR(s) suitable for TCR-gene therapy. 3. Eastern Cooperative Oncology Group (ECOG) performance s...